Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development
- PMID: 11390574
- PMCID: PMC114288
- DOI: 10.1128/JVI.75.13.5721-5729.2001
Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development
References
-
- Artenstein A W, VanCott T C, Mascola J R, Carr J K, Hegerich P A, Gaywee J, Sanders-Buell E, Robb M L, Dayhoff D E, Thitivichianlert S. Dual infection with human immunodeficiency virus type 1 of distinct envelope subtypes in humans. J Infect Dis. 1995;171:805–810. - PubMed
-
- Beddows S, Louisirirotchanakul S, Cheingsong-Popov R, Easterbrook P J, Simmonds P, Weber J. Neutralization of primary and T-cell line adapted isolates of human immunodeficiency virus type 1: role of V3-specific antibodies. J Gen Virol. 1998;79:77–82. - PubMed
-
- Beirnaert E, Nyambi P, Willems B, Heyndrickx L, Colebunders R, Janssens W, van der Groen G. Identification and characterization of sera from HIV-infected individuals with broad cross-neutralizing activity against group M (env clade A-H) and group O primary HIV-1 isolates. J Med Virol. 2000;62:14–24. - PubMed
-
- Berman P W. Development of bivalent rgp120 vaccines to prevent HIV type 1 infection. AIDS Res Hum Retrovir. 1998;14(Suppl. 3):S277–S289. - PubMed
-
- Berman P W, Gray A M, Wrin T, Vennari J C, Eastman D J, Nakamura G R, Fancis D P, Gorse G, Schwartz D H. Genetic and immunologic characterization of viruses infecting MN-rgp120-vaccinated volunteers. J Infect Dis. 1997;176:384–397. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
